Zai Lab Limited
ZLAB
Positions held
Your positionsZLAB isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Zai Lab operates in the biotechnology sector, which is poised for growth due to increasing demand for innovative therapies and personalized medicine.
- Revenue increased by 7% compared to the prior quarter, reaching $106 million.
- The target mean price for Zai Lab is $33.14, indicating potential upside from current levels.
- Zai Lab has a negative profit margin of -41.86%, reflecting ongoing challenges in achieving profitability.
- The company reported a net income loss of $50.825 million in the latest quarter.
- Zai Lab's revenue growth is currently at -3.3%, indicating a decline in sales performance.
Fundamentals
| Market cap | $2.79B | Enterprise value | $2.42B | Trailing P/E | — | Forward P/E | -11.76 |
| PEG | — | Price / book | 4.59 | Beta | 0.72 | Dividend yield | 0.00% |
| Revenue growth | -3.3% | Earnings growth | — | Gross margin | 3.8% | Operating margin | -71.9% |
| Profit margin | -41.9% | ROE | -26.9% | ROA | -14.7% | Debt / equity | 0.42 |
| Current ratio | 2.13 | Free cash flow | -$83.96M | Analyst recommendation | strong_buy | Mean target | $33.14 |
| 52w high | $33.65 | 52w low | $15.96 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $106M | $99.6M | $128M | $116M | $110M | — |
| Op margin | -71.9% | -69.5% | -53.5% | -41.3% | -49.9% | — |
| Net income | -$50.8M | -$51.0M | -$50.4M | -$36.0M | -$40.7M | — |
| Gross margin | 54.7% | 61.5% | 51.2% | 59.6% | 60.7% | — |
| Gross profit | $58.1M | $61.3M | $65.3M | $69.2M | $66.8M | — |
| Operating income | -$76.5M | -$69.3M | -$68.3M | -$48.0M | -$54.9M | — |
- Revenue +7% vs prior quarter ($106M vs $100M).
- Gross margin 54.7% (was 61.5% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $460M | $399M | $267M | $215M | — |
| Op margin | -48.6% | -68.7% | -140.3% | -182.7% | — |
| Net income | -$176M | -$257M | -$335M | -$443M | — |
| Gross margin | 58.5% | 62.9% | 64.1% | 65.6% | — |
| Gross profit | $269M | $251M | $171M | $141M | — |
| Operating income | -$224M | -$274M | -$374M | -$393M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
2026-10-08 · Asian Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
2026-10-06 · Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading
2026-10-04 · Is Zai Lab (ZLAB) Cheap After Its ESMO 2026 Lung Cancer Data Update?
2026-10-02 · Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; End Week Flat
2026-09-24 · Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading
2026-09-24 · Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
2026-09-14 · Big Pharma Is Pouring Billions Into China’s Biotechs
2026-09-06 · Zai Lab (ZLAB) Stock Looks Stretched On Sales But Reasonable On Broader Checks
2026-09-04 · Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading
2026-09-02 · Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
Price (daily)
Full chart · RSI · MACD · patterns